HomepageSGIOY • OTCMKTS
add
Shionogi
Vorige slotkoers
$Â 10,83
Dag-range
$Â 10,71 - $Â 10,79
Jaar-range
$Â 7,27 - $Â 12,00
Beurswaarde
3,07Â bln. JPY
Gem. volume
117,39K
Koers/winst
-
Dividendrendement
-
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (JPY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 147,72Â mld. | 23,48% |
Bedrijfskosten | 48,45Â mld. | -3,83% |
Netto inkomsten | 74,68Â mld. | 47,39% |
Netto winstmarge | 50,56 | 19,36% |
Winst per aandeel | — | — |
EBITDA | 80,21Â mld. | 36,44% |
Effectief belastingtarief | 19,60% | — |
Balans
Totale activa
Totale passiva
| (JPY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 215,60Â mld. | -29,45% |
Totale activa | 1,73Â bln. | 13,94% |
Totale passiva | 213,60Â mld. | 38,72% |
Totaal aandelenvermogen | 1,51 bln. | — |
Uitstaande aandelen | 850,98 mln. | — |
Koers-boekwaardeverhouding | 0,01 | — |
Rendement op activa | 11,09% | — |
Rendement op kapitaal | 12,36% | — |
Kasstroom
Nettomutatie in liquide middelen
| (JPY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 74,68Â mld. | 47,39% |
Operationele kasstroom | 32,03Â mld. | -21,48% |
Kasstroom uit beleggingen | -26,57Â mld. | -54,23% |
Kasstroom uit financiering | -29,20Â mld. | -17,14% |
Nettomutatie in liquide middelen | -18,27Â mld. | -940,68% |
Vrije kasstroom | -10,55Â mld. | -29.095,85% |
Over
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Opgericht
1878
Hoofdvestiging
Website
Werknemers
4.955